Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Cisplatin + Vinorelbine
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cisplatin Platinol CDDP Chemotherapy - Platinum 7 Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).
Vinorelbine Navelbine Vinorelbin Antimicrotubule Agent 14 Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06632327 Phase III Docetaxel + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pembrolizumab + Vinorelbine Carboplatin + Nivolumab + Vinorelbine Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Gemcitabine Docetaxel + Gemcitabine Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Atezolizumab + Cisplatin + Vinorelbine Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Vinorelbine Atezolizumab + Docetaxel + Gemcitabine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine + Nivolumab Atezolizumab Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Vinorelbine Docetaxel + Gemcitabine + Pembrolizumab Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Vinorelbine Cisplatin + Pembrolizumab + Vinorelbine Atezolizumab + Carboplatin + Pemetrexed Disodium Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer Not yet recruiting USA 0
NCT05383001 Phase II Cisplatin + Vinorelbine Carboplatin + Vinorelbine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Nab-paclitaxel Durvalumab + Tremelimumab Carboplatin + Nab-paclitaxel Cisplatin + Gemcitabine Carboplatin + Gemcitabine Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) Withdrawn DEU 0


Additional content available in CKB BOOST